Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Andressa Dias Costa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1046-4899; OpenAlex author ID A5072851865, A5136917429. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
98
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers · 2025: none · 2026: 2 papers

Papers 16

  1. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. First author DOI 10.1038/s43018-026-01165-8↗
  2. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Co-author DOI 10.64898/2026.04.02.26349987↗
  3. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
  4. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  5. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0873↗
  6. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… First author DOI 10.1158/2326-6066.cir-23-1073↗
  7. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline r… Co-author DOI 10.1136/jitc-2023-007586↗
  8. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. First author DOI 10.1158/0008-5472.can-22-3050↗
  9. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  10. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  11. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  12. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  13. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  14. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cell.2020.03.062↗
  15. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  16. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma Co-author DOI 10.1101/663583↗

Closest collaborators

The 25 strongest of 98 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 16 shared papers, 2019–2026 · strength 1.93
  2. Jonathan Andrew Nowak · 16 shared papers, 2019–2026 · strength 1.93
  3. Kimberly J. Perez · 8 shared papers, 2020–2026 · strength 1.03
  4. Andrew J. Aguirre · 8 shared papers, 2020–2026 · strength 0.98
  5. James M. Cleary · 7 shared papers, 2021–2026 · strength 0.95
  6. Douglas Adam Rubinson · 8 shared papers, 2020–2026 · strength 0.87
  7. Harshabad Singh · 6 shared papers, 2022–2026 · strength 0.87
  8. Thomas E. Clancy · 7 shared papers, 2020–2024 · strength 0.72
  9. Sara A. Väyrynen · 8 shared papers, 2019–2023 · strength 0.71
  10. Stephanie K. Dougan · 5 shared papers, 2022–2024 · strength 0.70
  11. Chen Yuan · 6 shared papers, 2020–2024 · strength 0.63
  12. Hannah L. Williams · 5 shared papers, 2021–2024 · strength 0.54
  13. Albert C. Koong · 6 shared papers, 2019–2023 · strength 0.53
  14. Richard Francis Dunne · 6 shared papers, 2019–2023 · strength 0.53
  15. Daniel Tandel Chang · 6 shared papers, 2019–2023 · strength 0.53
  16. Aram F. Hezel · 6 shared papers, 2019–2023 · strength 0.53
  17. Srivatsan Raghavan · 4 shared papers, 2021–2026 · strength 0.53
  18. Osama E. Rahma · 4 shared papers, 2021–2024 · strength 0.53
  19. Vicente Morales‐Oyarvide · 5 shared papers, 2020–2023 · strength 0.48
  20. Thomas Adam Abrams · 3 shared papers, 2024–2026 · strength 0.48
  21. Jiping Wang · 4 shared papers, 2021–2024 · strength 0.47
  22. Brandon M. Huffman · 3 shared papers, 2024–2026 · strength 0.47
  23. Rishi Surana · 3 shared papers, 2024–2026 · strength 0.47
  24. Lisa M. Coussens · 4 shared papers, 2021–2024 · strength 0.46
  25. Kimmie Ng · 4 shared papers, 2020–2026 · strength 0.44

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.